Health
Ozempic, Wegovy may be linked to stomach paralysis and other digestive issues in large-scale study
Popular weight loss drugs like Wegovy and Ozempic could increase the risk of stomach paralysis as well as several other serious gastrointestinal conditions, according to a study published Thursday in JAMA.
This was the first large epidemiological (disease-related) study to examine these adverse effects in non-diabetic patients using the drugs specifically for weight loss, per a press release from The University of British Columbia (UBC).
The risk was linked to all semaglutides, a class of medications known as GLP-1 receptor agonists — including Ozempic (prescribed for diabetes management), Wegovy (prescribed for weight loss), Rybelsus (type 2 diabetes) and Saxenda (weight loss).
OZEMPIC DIABETES AND WEIGHT LOSS MEDICATION UNDER INVESTIGATION AFTER A FEW REPORTS OF SUICIDAL THOUGHTS
Stomach paralysis, officially known as gastroparesis, prevents the nerves and muscles in the stomach from moving food into the small intestine, which keeps digestion from occurring, as described on Cleveland Clinic’s website.
In addition to stomach paralysis, the drugs were linked to a greater risk of pancreatitis (inflammation of the pancreas) and bowel obstruction, which prevents food from passing through the small or large intestine, the release stated.
UBC researchers examined the health insurance claim records for approximately 16 million U.S. patients who were prescribed Ozempic, Wegovy or either semaglutide or liraglutide medications across a 14-year span (between 2006 and 2020).
The researchers could not assess whether the condition was temporary or permanent.
Compared to another weight loss drug, bupropion-naltrexone, those who took a GLP-1 agonist were 3.67 times more likely to develop stomach paralysis, had a 9.09 times higher risk of pancreatitis and were 4.22 times more likely to have bowel obstruction.
OZEMPIC, WEGOVY AND ALL THOSE CRAZY, VIVID DREAMS: IS THERE A CONNECTION?
For the cases of stomach paralysis, the researchers could not assess whether the condition was temporary or permanent.
“There are reports from other journalists where they have met patients whose symptoms have not gone away despite stopping the drugs,” study co-author Dr. Mahyar Etminan, associate professor in the Departments of Ophthalmology & Visual Sciences and Medicine at UBC, told Fox News Digital.
There are medications that can be used to help with the condition, he added.
Although these complications were rare, the researchers found them concerning, given that millions of people are using these medications worldwide.
The number of people in the U.S. using GLP-1 agonists for either diabetes or obesity reached 40 million in 2022, they noted.
“These drugs are becoming increasingly accessible, and it is concerning that, in some cases, people can simply go online and order these kinds of medications when they may not have a full understanding of what could potentially happen,” said first author Mohit Sodhi, a graduate of UBC’s experimental medicine program, in the release.
The number of people in the U.S. using GLP-1 agonists for either diabetes or obesity reportedly reached 40 million in 2022.
“Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss.”
The researchers recommend that regulatory agencies and drugmakers consider updating the warning labels for their products, which currently don’t include the risk of gastroparesis.
“This is critical information for patients to know so they can seek timely medical attention and avoid serious consequences,” said Sodhi.
The decision about whether to take the drug in spite of these risks will depend on each patient’s individual situation, the researchers said.
“This decision should be individually assessed,” said Etminan. “There are patients where the benefit of the drugs might outweigh the risks (very obese individuals), whereas in other situations (healthy individuals who just want to lose a few pounds), the risks might outweigh the benefits.”
“This is critical information for patients to know so they can seek timely medical attention and avoid serious consequences.”
The study did have some limitations, the researchers noted.
“We did not have access to medical charts to ascertain all subjects’ medical histories,” said Etminan. “Also, we could not look at risk with individual GLP-1 drugs, but this is probably a class effect of these drugs.”
OZEMPIC-WEGOVY PILL MAY BE ON THE WAY: TRIAL SHOWS PROMISING RESULTS FOR NEW WEIGHT LOSS TABLET
The researchers also did not determine whether certain groups were at higher risk of this adverse side effect, but Etminan said he suspects that those with preexisting GI conditions might be more susceptible.
California-based cardiologist Dr. Ernst von Schwarz, author of “The Secrets of Immortality,” was not involved in the study but noted that it confirmed a higher prevalence of pancreatitis, gastroparesis and bowel obstruction in patients on GLP-1 agonists.
“On the other hand, these drugs have been shown to reduce the risk of cardiovascular events as shown for Ozempic in 2016 in diabetics and in 2023 for Wegovy,” he said in an interview with Fox News Digital.
“The achieved weight loss using GLP-1 agonists, as well as the improved glucose control, seem to have significant benefits on cardiovascular outcomes, but patients need to be informed about the relatively small incidence of abdominal side effects as seen in this cohort study,” said von Schwarz.
“The benefits on cardiovascular risks, however, appear to outweigh the risks of side effects.”
The U.S. Food and Drug Administration (FDA) lists “ileus” as a potential side effect of Ozempic.
Ileus is the inability of the intestine (bowel) to contract normally and move waste out of the body, according to Mayo Clinic.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
In August, a Louisiana woman sued Novo Nordisk, the manufacturer of Ozempic and Wegovy, and Lilly, which makes another GLP-1 agonist, Mounjaro, claiming that the companies “downplayed the severity of gastrointestinal events caused by Ozempic and Mounjaro — never, for example, warning of the risk of gastroparesis (‘paralyzed stomach’) or gastroenteritis.”
The woman, who used Ozempic for more than a year before switching to Mounjaro last month, alleged she was “severely injured as a result” of using both drugs, the suit stated.
In a statement at the time, a spokesperson for Novo Nordisk told FOX Business that gastrointestinal events “are well-known side effects of the GLP-1 class” and “are mild to moderate in severity and of short duration.”
“Given the wide use of these drugs, these adverse events, although rare, must be considered by patients thinking about using them for weight loss.”
The company provided the below statement to Fox News Digital on Friday, Oct. 6.
“At Novo Nordisk, patient safety is a top priority. We work closely with the U.S. Food and Drug Administration to continuously monitor the safety profile of our medicines. The FDA-approved product labeling for Novo Nordisk’s GLP-1RA medicines indicated for use in weight management (Saxenda and Wegovy) includes information about their potential side effects, including pancreatitis, acute gallbladder disease, ileus and delayed gastric emptying.”
“Similar information is included in the product labeling for our GLP-1RA medicines indicated for the treatment of type 2 diabetes (Ozempic, Rybelsus and Victoza),” the statement went on.
“Novo Nordisk stands behind the safety and efficacy of all of our GLP-1RA medicines when used consistent with the product labeling and approved indications.”
Novo Nordisk continued, “With respect to the study, as the authors acknowledge, the study has limitations, including potential confounding by indication and by other factors.”
The company added, “It is also important to note that the study analyzed data collected during the period between 2006 and 2020. During this time, Wegovy was not on the market; Saxenda was first approved in December 2014. In addition, Victoza was FDA-approved in January 2010 and Ozempic was FDA-approved in December 2017.”
Daniella Genovese of Fox News Digital contributed to this report.
For more Health articles, visit www.foxnews.com/health.
Health
How Yvette Nicole Brown Lost Weight and Got Her Diabetes Under Control
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Health
As bird flu spreads, CDC recommends faster 'subtyping' to catch more cases
As cases of H5N1, also known as avian flu or bird flu, continue to surface across the U.S., safety precautions are ramping up.
The U.S. Centers for Disease Control and Prevention (CDC) announced on Thursday its recommendation to test hospitalized influenza A patients more quickly and thoroughly to distinguish between seasonal flu and bird flu.
The accelerated “subtyping” of flu A in hospitalized patients is in response to “sporadic human infections” of avian flu, the CDC wrote in a press release.
ONE STATE LEADS COUNTRY IN HUMAN BIRD FLU WITH NEARLY 40 CONFIRMED CASES
“CDC is recommending a shortened timeline for subtyping all influenza A specimens among hospitalized patients and increasing efforts at clinical laboratories to identify non-seasonal influenza,” the agency wrote.
“Clinicians and laboratorians are reminded to test for influenza in patients with suspected influenza and, going forward, to now expedite the subtyping of influenza A-positive specimens from hospitalized patients, particularly those in an intensive care unit (ICU).”
LOUISIANA REPORTS FIRST BIRD FLU-RELATED HUMAN DEATH IN US
The goal is to prevent delays in identifying bird flu infections and promote better patient care, “timely infection control” and case investigation, the agency stated.
These delays are more likely to occur during the flu season due to high patient volumes, according to the CDC.
For more Health articles, visit www.foxnews.com/health
Health care systems are expected to use tests that identify seasonal influenza A as a subtype – so if a test comes back positive for influenza A but negative for seasonal influenza, that is an indicator that the detected virus might be novel.
“Subtyping is especially important in people who have a history of relevant exposure to wild or domestic animals [that are] infected or possibly infected with avian influenza A (H5N1) viruses,” the CDC wrote.
In an HHS media briefing on Thursday, the CDC confirmed that the public risk for avian flu is still low, but is being closely monitored.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The agency spokesperson clarified that this accelerated testing is not due to bird flu cases being missed, as the CDC noted in its press release that those hospitalized with influenza A “probably have seasonal influenza.”
Niels Riedemann, MD, PhD, CEO and founder of InflaRx, a German biotechnology company, said that understanding these subtypes is an “important step” in better preparing for “any potential outbreak of concerning variants.”
“It will also be important to foster research and development of therapeutics, including those addressing the patient’s inflammatory immune response to these types of viruses – as this has been shown to cause organ injury and death during the COVID pandemic,” he told Fox News Digital.
Since 2022, there have been 67 total human cases of bird flu, according to the CDC, with 66 of those occurring in 2024.
The CDC recommends that people avoid direct contact with wild birds or other animals that are suspected to be infected. Those who work closely with animals should also wear the proper personal protective equipment (PPE).
Health
Sick Prisoners in New York Were Granted Parole but Remain Behind Bars
When the letter arrived at Westil Gonzalez’s prison cell saying that he had been granted parole, he couldn’t read it. Over the 33 years he had been locked up for murder, multiple sclerosis had taken much of his vision and left him reliant on a wheelchair.
He had a clear sense of what he would do once freed. “I want to give my testimony to a couple of young people who are out there, picking up guns,” Mr. Gonzalez, 57, said in a recent interview. “I want to save one person from what I’ve been through.”
But six months have passed, and Mr. Gonzalez is still incarcerated outside Buffalo, because the Department of Corrections has not found a nursing home that will accept him. Another New York inmate has been in the same limbo for 20 months. Others were released only after suing the state.
America’s elderly prison population is rising, partly because of more people serving long sentences for violent crimes. Nearly 16 percent of prisoners were over 55 in 2022, up from 5 percent in 2007. The share of prisoners over 65 quadrupled over the same time period, to about 4 percent.
Complex and costly medical conditions require more nursing care, both in prison and after an inmate’s release. Across the country, prison systems attempting to discharge inmates convicted of serious crimes often find themselves with few options. Nursing home beds can be hard to find even for those without criminal records.
Spending on inmates’ medical care is increasing — in New York, it has grown to just over $7,500 in 2021 from about $6,000 per person in 2012. Even so, those who work with the incarcerated say the money is often not enough to keep up with the growing share of older inmates who have chronic health problems.
“We see a lot of unfortunate gaps in care,” said Dr. William Weber, an emergency physician in Chicago and medical director of the Medical Justice Alliance, a nonprofit that trains doctors to work as expert witnesses in cases involving prison inmates. With inmates often struggling to get specialty care or even copies of their own medical records, “things fall through the cracks,” he said.
Dr. Weber said he was recently involved in two cases of seriously ill prisoners, one in Pennsylvania and the other in Illinois, who could not be released without a nursing home placement. The Pennsylvania inmate died in prison and the Illinois man remains incarcerated, he said.
Almost all states have programs that allow early release for inmates with serious or life-threatening medical conditions. New York’s program is one of the more expansive: While other states often limit the policy to those with less than six months to live, New York’s is open to anyone with a terminal or debilitating illness. Nearly 90 people were granted medical parole in New York between 2020 and 2023.
But the state’s nursing home occupancy rate hovers around 90 percent, one of the highest in the nation, making it especially hard to find spots for prisoners.
The prison system is “competing with hospital patients, rehabilitation patients and the general public that require skilled nursing for the limited number of beds available,” said Thomas Mailey, a spokesman for the New York Department of Corrections and Community Supervision. He declined to comment on Mr. Gonzalez’s case or on any other inmate’s medical conditions.
Parolees remain in the state’s custody until their original imprisonment term has expired. Courts have previously upheld the state’s right to place conditions on prisoner releases to safeguard the public, such as barring paroled sex offenders from living near schools.
But lawyers and medical ethicists contend that paroled patients should be allowed to choose how to get their care. And some noted that these prisoners’ medical needs are not necessarily met in prison. Mr. Gonzalez, for example, said he had not received glasses, despite repeated requests. His disease has made one of his hands curl inward, leaving his unclipped nails to dig into his palm.
“Although I’m sympathetic to the difficulty of finding placements, the default solution cannot be continued incarceration,” said Steven Zeidman, director of the criminal defense clinic at CUNY School of Law. In 2019, one of his clients died in prison weeks after being granted medical parole.
New York does not publish data on how many inmates are waiting for nursing home placements. One 2018 study found that, between 2013 and 2015, six of the 36 inmates granted medical parole died before a placement could be found. The medical parole process moves slowly, the study showed, sometimes taking years for a prisoner to even get an interview about their possible release.
Finding a nursing home can prove difficult even for a patient with no criminal record. Facilities have struggled to recruit staff, especially since the coronavirus pandemic. Nursing homes may also worry about the safety risk of someone with a prior conviction, or about the financial risk of losing residents who do not want to live in a facility that accepts former inmates.
“Nursing homes have concerns and, whether they are rational or not, it’s pretty easy not to pick up or return that phone call,” said Ruth Finkelstein, a professor at Hunter College who specializes in policies for older adults and reviewed legal filings at The Times’s request.
Some people involved in such cases said that New York prisons often perform little more than a cursory search for nursing care.
Jose Saldana, the director of a nonprofit called the Release Aging People in Prison Campaign, said that when he was incarcerated at Sullivan Correctional Facility from 2010 through 2016, he worked in a department that helped coordinate parolees’ releases. He said he often reminded his supervisor to call nursing homes that hadn’t picked up the first time.
“They would say they had too many other responsibilities to stay on the phone calling,” Mr. Saldana said.
Mr. Mailey, the spokesman for the New York corrections department, said that the agency had multiple discharge teams seeking placement options.
In 2023, Arthur Green, a 73-year-old patient on kidney dialysis, sued the state for release four months after being granted medical parole. In his lawsuit, Mr. Green’s attorneys said that they had secured a nursing home placement for him, but that it lapsed because the Department of Corrections submitted an incomplete application to a nearby dialysis center.
The state found a placement for Mr. Green a year after his parole date, according to Martha Rayner, an attorney who specializes in prisoner release cases.
John Teixeira was granted medical parole in 2020, at age 56, but remained incarcerated for two and a half years, as the state searched for a nursing home. He had a history of heart attacks and took daily medications, including one delivered through an intravenous port. But an assessment from an independent cardiologist concluded that Mr. Teixeira did not need nursing care.
Lawyers with the Legal Aid Society in New York sued the state for his release, noting that during his wait, his port repeatedly became infected and his diagnosis progressed from “advanced” to “end-stage” heart failure.
The Department of Corrections responded that 16 nursing homes had declined to accept Mr. Teixeira because they could not manage his medical needs. The case resolved three months after the suit was filed, when “the judge put significant pressure” on the state to find an appropriate placement, according to Stefen Short, one of Mr. Teixeira’s lawyers.
Some sick prisoners awaiting release have found it difficult to get medical care on the inside.
Steve Coleman, 67, has trouble walking and spends most of the day sitting down. After 43 years locked up for murder, he was granted parole in April 2023 and has remained incarcerated, as the state looks for a nursing home that could coordinate with a kidney dialysis center three times each week.
But Mr. Coleman has not had dialysis treatment since March, when the state ended a contract with its provider. The prison has offered to take Mr. Coleman to a nearby clinic for treatment, but he has declined because he finds the transportation protocol — which involves a strip search and shackles — painful and invasive.
“They say you’ve got to go through a strip search,” he said in a recent interview. “If I’m being paroled, I can’t walk and I’m going to a hospital, who could I be hurting?”
Volunteers at the nonprofit Parole Prep Project, which assisted Mr. Coleman with his parole application, obtained a letter from Mount Sinai Hospital in New York City in June offering to give him medical care and help him transition back into the community.
Still incarcerated two months later, Mr. Coleman sued for his release.
In court filings, the state argued that it would be “unsafe and irresponsible” to release Mr. Coleman without plans to meet his medical needs. The state also said that it had contacted Mount Sinai, as well as hundreds of nursing homes, about Mr. Coleman’s placement and had never heard back.
In October, a court ruled in the prison system’s favor. Describing Mr. Coleman’s situation as “very sad and frustrating,” Justice Debra Givens of New York State Supreme Court concluded that the state had a rational reason to hold Mr. Coleman past his parole date. Ms. Rayner, Mr. Coleman’s lawyer, and the New York Civil Liberties Union appealed the ruling on Wednesday.
Fourteen medical ethicists have sent a letter to the prison supporting Mr. Coleman’s release. “Forcing continued incarceration under the guise of ‘best interests,’ even if doing so is well-intentioned, disregards his autonomy,” they wrote.
Several other states have come up with a different solution for people on medical parole: soliciting the business of nursing homes that specialize in housing patients rejected elsewhere.
A private company called iCare in 2013 opened the first such facility in Connecticut, which now houses 95 residents. The company runs similar nursing homes in Vermont and Massachusetts.
David Skoczulek, iCare’s vice president of business development, said that these facilities tend to save states money because the federal government covers some of the costs through Medicaid.
“It’s more humane, less restrictive and cost-effective,” he said. “There is no reason for these people to remain in a corrections environment.”
-
Technology1 week ago
Meta is highlighting a splintering global approach to online speech
-
Science6 days ago
Metro will offer free rides in L.A. through Sunday due to fires
-
Technology1 week ago
Las Vegas police release ChatGPT logs from the suspect in the Cybertruck explosion
-
News1 week ago
Photos: Pacific Palisades Wildfire Engulfs Homes in an L.A. Neighborhood
-
Education1 week ago
Four Fraternity Members Charged After a Pledge Is Set on Fire
-
Politics1 week ago
Trump trolls Canada again, shares map with country as part of US: 'Oh Canada!'
-
Technology6 days ago
Amazon Prime will shut down its clothing try-on program
-
News1 week ago
Mapping the Damage From the Palisades Fire